Arodys Vizcaino Injury Update: Braves Pitcher Will Have Elbow Examined On Monday

The Atlanta Braves are currently struggling in Spring Training, but it now appears as though one of their pitchers is experiencing some pre-season medical woes.

David O'Brien of the Atlanta Journal-Constitution reports that Braves pitcher Arodys Vizcaino has been diagnosed with ulnar neuritis in his elbow, but requires further examination. The player will have his elbow looked at by a doctor on Monday.

O'Brien followed up by saying that Vizcaino partially tore the ulnar collateral ligament in question back in 2010. At that time, the ligament was allowed to heal without surgery.

Vizcaino was called up to the Braves in August of 2011 and made his MLB debut as a reliever. His current MLB stats are a 1-1 record, with 4.67 ERA and 17 strikeouts. He is considered to be among the top prospects in the Braves system.

For all news and information regarding the Atlanta Braves, please visit Talking Chop or stay tuned to SB Nation Atlanta.

In This Article

Teams

Trending Discussions

X
Log In Sign Up

forgot?
Log In Sign Up

Forgot password?

We'll email you a reset link.

If you signed up using a 3rd party account like Facebook or Twitter, please login with it instead.

Forgot password?

Try another email?

Almost done,

Join SB Nation Atlanta

You must be a member of SB Nation Atlanta to participate.

We have our own Community Guidelines at SB Nation Atlanta. You should read them.

Join SB Nation Atlanta

You must be a member of SB Nation Atlanta to participate.

We have our own Community Guidelines at SB Nation Atlanta. You should read them.

Spinner.vc97ec6e

Authenticating

Great!

Choose an available username to complete sign up.

In order to provide our users with a better overall experience, we ask for more information from Facebook when using it to login so that we can learn more about our audience and provide you with the best possible experience. We do not store specific user data and the sharing of it is not required to login with Facebook.